Want to join the conversation?
$GILD's research and development expenses for 3Q15 rose by 18% from last year, on $77MM related to clinical study activity, particularly due to continued progression of clinical studies in HIV TAF-based programs. Selling, general and administrative expenses fell by 4% on $197MM decline in non-tax deductible branded prescription drug fee.
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.